Annual report pursuant to Section 13 and 15(d)

4. Significant Strategic Drug Development Collaborations (Details Narrative)

v3.3.1.900
4. Significant Strategic Drug Development Collaborations (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Shares issued for equity investment, value $ 337,340 $ 10,811,196  
Research, development, license and supply agreement [Member] | Baxalta [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Shares issued for equity investment, shares   10,695,187  
Shares issued for equity investment, value   $ 10,000,000  
Revenue recognized     $ 1,000,000
Percent ownership in Xenetic 8.00% 8.70%  
Stock subscription and collaborative development agreement [Member] | SynBio LLC [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Revenue recognized $ 0    
Percent ownership in Xenetic 39.00% 41.60%  
Warrant granted to purchase common stock, common shares available for purchase   6,745,000  
License and supply agreements [Member] | Serum Institute of India Ltd [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Revenue recognized $ 0    
Percent ownership in Xenetic 8.50% 9.20%  
Warrant granted to purchase common stock, common shares available for purchase   3,200,000